400 related articles for article (PubMed ID: 31880964)
1. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
McLouth LE; Zheng Y; Smith S; Hodi FS; Rao UN; Cohen GI; Amatruda TT; Dakhil SR; Curti BD; Nakhoul I; Chandana SR; Bane CL; Marinier DE; Lee SJ; Sondak VK; Kirkwood JM; Tarhini AA; Wagner LI
Qual Life Res; 2023 Jan; 32(1):183-196. PubMed ID: 36029412
[TBL] [Abstract][Full Text] [Related]
3. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
4. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M; Lee SJ; Tan AC; El Naqa IM; Hodi FS; Butterfield LH; LaFramboise WA; Storkus W; Karunamurthy AD; Conejo-Garcia J; Hwu P; Streicher H; Sondak VK; Kirkwood JM; Tarhini AA
J Transl Med; 2022 Jun; 20(1):253. PubMed ID: 35659704
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
8. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
11. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
14. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
16. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
17. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
18. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
19. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Therapy for Melanoma.
Agha A; Tarhini AA
Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
